摘要
目的观察托伐普坦联合贝前列素钠治疗肺动脉高压致右心衰竭的临床效果。方法选取2018年4月—2019年4月九江市第一人民医院收治的60例肺动脉高压致右心衰竭患者,按随机数字表法分为A、B、C、D组,每组15例。A组采取常规方案治疗,B组在A组的基础上采用贝前列素钠治疗,C组在A组基础上采用托伐普坦,D组在A组的基础上采用托伐普坦联合贝前列素钠治疗,4组均连续治疗20 d。比较4组患者治疗前后心功能指标[右心室射血分数(RVEF)、右心室舒张末期容积(RVEDV)、右心室每搏输出量(RVSV)]、生活质量[健康状况调查简表(SF-36)]、血气分析指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))],并观察4组不良反应。结果治疗后,4组RVEF、RVSV、RVEDV比较,差异有统计学意义(P<0.05),其中D组RVEF高于A、B、C组,RVSV、RVEDV低于A、B、C组(P<0.05)。治疗后,4组PaO_(2)、PaCO_(2)比较,差异有统计学意义(P<0.05),其中D组PaO_(2)低于A、B、C组,PaCO_(2)高于A、B、C组(P<0.05)。治疗后,4组SF-36评分比较,差异有统计学意义(P<0.05),其中D组SF-36评分高于A、B、C组(P<0.05)。4组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论托伐普坦联合贝前列素钠治疗肺动脉高压致右心衰竭患者,可明显改善其心功能、生活质量,并不会增加不良反应。
Objective To analyze the clinical effect of tovaptan combined with beprost sodium in the treatment of patients with right heart failure caused by pulmonary hypertension.Methods Sixty patients with right heart failure caused by pulmonary hypertension treated in Jiujiang First People′s Hospital from April 2018 to April 2019 were randomly divided into groups A,B,C and D,with 15 cases in each group.Group A was treated with routine regimen,and group B was treated with beprost sodium based on group A,group C was treated with tolvaptan based on group A,and group D was treated with tolvaptan combined with beprost sodium based on group A.All four groups were treated for 20 days.The cardiac function indexes[right ventricular ejection fraction(RVEF),right ventricular end diastolic volume(RVEDV),right ventricular stroke output(rVSV)],quality of life[brief form of Health Survey(SF-36)],blood gas index[arterial partial pressure of oxygen(PaO_(2)),partial pressure of carbon dioxide(PaCO_(2))]were compared before and after treatment in four groups.The adverse reactions of the four groups were observed.Results After treatment,there was significant difference in RVEF,rVSV and rvedv among the four groups(P<0.05);among them,RVEF in group D was higher than that in groups A,B and C,and RVSV and RVEDV were lower than those in groups A,B and C(P<0.05).After treatment,there was significant difference in PaO_(2)and PaCO_(2)among the four groups(P<0.05);PaO_(2)in group D was lower than that in groups A,B and C,and PaCO_(2)was higher than that in groups A,B and C(P<0.05).After treatment,there was significant difference in SF-36 scores among the four groups (P<0.05);among them,the SF-36 scores in group D were higher than those in groups A,B and C(P<0.05).There was no significant difference in the total incidence of adverse reactions among the four groups (P>0.05).Conclusion Tovaptan combined with beprost sodium in the treatment of patients with right heart failure caused by pulmonary hypertension can significantly improve their cardiac fun
作者
朱保成
张佳秀
ZHU Baocheng;ZHANG Jiaxiu(Department of Cardiology,Jiujiang First People′s Hospital,Jiujiang 332000,China)
出处
《临床合理用药杂志》
2022年第6期5-8,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
肺动脉高压
右心衰竭
托伐普坦
贝前列素钠
心功能
血气指标
不良反应
Pulmonary hypertension
Right heart failure
Tovaptan
Beprost sodium
Cardiac function
Blood gas index
Adverse reactions
